

POSTER PRESENTATION

Open Access

Systemic delivery of TLR9-activating/STAT3-blocking oligonucleotides induces leukemia regression

Qifang Zhang, Dewan Md Sakib Hossain, Sergey Nechaev, Ralf Buettner, Piotr Swiderski, Agnieszka Jozwiak, Stephen J Forman, Ravi Bhatia, Ya-Huei Kuo, Marcin Kortylewski*

From Society for Immunotherapy of Cancer 29th Annual Meeting
National Harbor, MD, USA. 6-9 November 2014

Inhibition of transcription factors (TF) that drive tumor progression and immune evasion, such as STAT3, remains a challenge for pharmacological drugs. Blocking STAT3 binding to DNA using specific decoy oligodeoxynucleotides (dODN) provides an alternative targeted inhibitory strategy. To achieve STAT3 inhibition specifically in antigen-presenting cells, we linked STAT3dODN to a TLR9 ligand, CpG ODN as successfully done before for delivery of siRNA molecules [1,2]. The CpG-STAT3dODN conjugates are quickly internalized by both human and mouse TLR9-positive target cells, such as dendritic cells (DCs), macrophages and B lymphocytes as well as by myeloid leukemia and B lymphoma cells. In contrast, the uptake of unconjugated decoy molecules by immune cells was minimal as expected. After uptake, CpG-STAT3dODN molecules bind and sequester activated STAT3 proteins, thereby inhibiting their transcriptional activity as verified using confocal microscopy, gel retardation and reporter gene assays. The hairpin design and partial phosphorothioation of the backbone increases half-life of the CpG-STAT3dODN in human serum to over 48 h. Therefore, we assessed the feasibility of using CpG-STAT3dODNs for systemic administration against disseminated human TLR9+ acute myeloid leukemia (AML). As shown in xenotransplanted MV4-11 AML model, repeated daily intravenous injections of CpG-STAT3dODN (5 mg/kg) resulted in potent and direct antitumor effects. CpG-STAT3dODN, but not control conjugates, effectively eliminated leukemic cells from all tested organs including bone marrow within two weeks from the initiation of the study. The antitumor efficacy of this strategy is greatly enhanced in immunocompetent mice. Systemic administration of

CpG-STAT3dODN induced regression of the syngeneic mouse *Cbfb/MYH11* leukemia from blood, spleen and bone marrow within 12 days of treatment (Figure 1A). The two pronged, cytotoxic and immunostimulatory effects of this strategy resulted in long-term survival of




Figure 1

City of Hope Cancer Center, Duarte, Duarte, CA, USA

the majority of mice (Figure 1B). The potent immune activation was associated with enhanced expression of antigen-presenting and co-stimulatory molecules not only on the surface of DCs but also on differentiating AML cells. These immunostimulatory effects correlated with activation and infiltration of CD8⁺ T cells into various organs with concomitant reduction in regulatory T cell numbers. Our findings highlight the potential of using CpG-STAT3dODN for the two-pronged TLR9/STAT3-targeted immunotherapy of human AML and potentially other TLR9-positive blood cancers.

This project described was supported by the National Cancer Institute of the National Institutes of Health under award number R01CA155367 to M.K.

Published: 6 November 2014

References

1. Kortylewski M, Swiderski P, Herrmann A, *et al*: In vivo delivery of siRNA to immune cells by conjugation to a TLR9 agonist enhances antitumor immune responses. *Nat Biotechnol* 2009, **27**:925-932.
2. Zhang Q, Hossain DM, Nechaev S, *et al*: TLR9-mediated siRNA delivery for targeting of normal and malignant human hematopoietic cells in vivo. *Blood* 2013, **121**:1304-1315.0.

doi:10.1186/2051-1426-2-S3-P107

Cite this article as: Zhang *et al.*: Systemic delivery of TLR9-activating/STAT3-blocking oligonucleotides induces leukemia regression. *Journal for ImmunoTherapy of Cancer* 2014 **2**(Suppl 3):P107.

Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at
www.biomedcentral.com/submit

